Market Overview

St. Jude Announces First Implant in Pivotal Phase of Trial Evaluating AMPLATZER Plug


St. Jude Medical, Inc. (NYSE: STJ), a global medical device company, today announced the first patient implant in a new pivotal trial evaluating the company's AMPLATZER^™ Cardiac Plug (ACP) for the prevention of stroke. The AMPLATZER^™ Cardiac Plug Clinical Trial (ACP Trial) is designed to determine if the ACP device is safe and effective in preventing thrombus (blood clots) from migrating out of the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AF) who have a high risk for stroke.

The ACP Trial is a prospective, randomized, multi-center clinical study with an adaptive trial design that will enroll no fewer than 400 and no more than 3,000 patients at up to 90 sites in the U.S. and Canada. The trial compares the safety and efficacy of the ACP device to traditional medical treatment using long-term, blood-thinning medication.

Posted-In: News


Related Articles (STJ)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Fugro 2012 Net Profit Rises 1.4%

BNY Mellon Wins Key Patents for Processes Used in Commodities ETFs